Transgene and BioInvent - First patient treated in Part B of Phase I trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA® (pembrolizumab)

information fournie par Boursorama CP •10/10/2023 à 07:30

The Phase I Part B will evaluate the combination of BT-001 and pembrolizumab in solid tumors, including melanoma

Strasbourg, France, and Lund, Sweden, October 10, 2023, 7:30 am CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announce that the first patient of the Phase I part B clinical trial evaluating the combination of BT-001 and MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) has been dosed.

.../...